Skip to main content
Top
Published in: Malaria Journal 1/2015

Open Access 01-12-2015 | Research

In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013

Authors: Hui Liu, Heng-lin Yang, Lin-hua Tang, Xing-liang Li, Fang Huang, Jia-zhi Wang, Chun-fu Li, Heng-ye Wang, Ren-hua Nie, Xiang-rui Guo, Ying-xue Lin, Mei Li, Jian Wang, Jian-wei Xu

Published in: Malaria Journal | Issue 1/2015

Login to get access

Abstract

Background

Artemisinin-based combination therapy (ACT) is the recommended first-line treatment of falciparum malaria in all endemic countries. Artemisinin resistance in Plasmodium falciparum has been confirmed in the Greater Mekong subregion (GMS). Dihydroartemisinin-piperaquine (DAPQ) is the most commonly used ACT in China. To understand the DAPQ sensitivity of P. falciparum, DAPQ resistance was monitored in vivo along the China-Myanmar border from 2007 to 2013.

Methods

Eligible patients with mono-infections of P. falciparum were recruited to this study after obtaining full informed consent. DAPQ tablets for different categories of kg body weight ranges were given once a day for three days. Patients were followed up for 42 days. Polymerase chain reaction (PCR) was conducted to distinguish between re-infection and recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome was assessed according to the WHO recommended standards.

Results

243 patients were completed valid follow-up. The fever clearance time (FCT) and asexual parasite clearance times (APCT) were, respectively, 36.5 ± 10.9 and 43.5 ± 11.8 hours, and there was an increasing trend of both FCT (F = 268.41, P < 0.0001) and APCT (F = 88.6, P < 0.0001) from 2007 to 2013. Eight (3.3%, 95% confidence interval, 1.4–6.4%) patients present parasitaemia on day three after medication; however they were spontaneous cure on day four. 241 (99.2%; 95% CI, 97.1–99.9%) of the patients were adequate clinical and parasitological response (ACPR) and the proportions of ACPR had not changed significantly from 2007 to 2013 (X2 = 2.81, P = 0.7288).

Conclusion

In terms of efficacy, DAPQ is still an effective treatment for falciparum malaria. DAPQ sensitivity in P. falciparum had not significantly changed along the China-Myanmar border of Yunnan Province, China. However more attentions should be given to becoming slower fever and parasite clearance.
Literature
1.
go back to reference WHO. World malaria report 2012. Geneva: World Health Organization; 2012. WHO. World malaria report 2012. Geneva: World Health Organization; 2012.
2.
go back to reference WHO. The global plan for artemisinin resistance containment. Geneva: World Health Organization; 2011. WHO. The global plan for artemisinin resistance containment. Geneva: World Health Organization; 2011.
3.
go back to reference Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays detect artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug response studies. Lancet Infect Dis. 2013;13:1043–9.CrossRefPubMed Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays detect artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug response studies. Lancet Infect Dis. 2013;13:1043–9.CrossRefPubMed
4.
go back to reference Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.CrossRefPubMed Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.CrossRefPubMed
5.
go back to reference Amaratunga C, Sreng S, Suon S, Phelps E, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851–8.CrossRefPubMedCentralPubMed Amaratunga C, Sreng S, Suon S, Phelps E, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851–8.CrossRefPubMedCentralPubMed
6.
go back to reference Amaratunga C, Mao S, Sreng S. Slow parasite clearance rates in response to artemether in patients with severe malaria. Lancet Infect Dis. 2013;13:113–4.CrossRefPubMed Amaratunga C, Mao S, Sreng S. Slow parasite clearance rates in response to artemether in patients with severe malaria. Lancet Infect Dis. 2013;13:113–4.CrossRefPubMed
7.
8.
go back to reference Phyo AP, Nkhoma S, Stepniewska K, Ashley E, Nair S, Gready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.CrossRefPubMedCentralPubMed Phyo AP, Nkhoma S, Stepniewska K, Ashley E, Nair S, Gready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.CrossRefPubMedCentralPubMed
9.
go back to reference Bangchang K, Karbwang J. Emerging artemisinin resistance in the border areas of Thailand. Clin Pharmacol. 2013;6:307–22. Bangchang K, Karbwang J. Emerging artemisinin resistance in the border areas of Thailand. Clin Pharmacol. 2013;6:307–22.
11.
go back to reference WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. p. 1–66. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. p. 1–66.
12.
go back to reference MOH of People’s Republic of China. From malaria control to elimination: a revised national malaria strategy 2010–2015. Beijing: Ministry of Health; 2009. p. 2–4. MOH of People’s Republic of China. From malaria control to elimination: a revised national malaria strategy 2010–2015. Beijing: Ministry of Health; 2009. p. 2–4.
13.
go back to reference MOH of People’s Republic of China. Malaria elimination action plan 2010–2020. Beijing: Ministry of Health; 2010. p. 1–2 [in Chinese]. MOH of People’s Republic of China. Malaria elimination action plan 2010–2020. Beijing: Ministry of Health; 2010. p. 1–2 [in Chinese].
14.
go back to reference MOH of People’s Republic of China. Malaria control manual. Beijing: Ministry of Health; 2007. p. 33–43 [in Chinese]. MOH of People’s Republic of China. Malaria control manual. Beijing: Ministry of Health; 2007. p. 33–43 [in Chinese].
16.
go back to reference Xu JW, Liu H. The challenges of malaria elimination in yunnan province, people’s republic of China. Southeast Asian J Trop Med Public Health. 2012;43:819–24.PubMed Xu JW, Liu H. The challenges of malaria elimination in yunnan province, people’s republic of China. Southeast Asian J Trop Med Public Health. 2012;43:819–24.PubMed
17.
go back to reference Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 2011;585:1551–62.CrossRefPubMed Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 2011;585:1551–62.CrossRefPubMed
18.
go back to reference Bräutigam D. Local entrepreneurship in Southeast Asia and Subsaharan Africa: networks and linkages to the global economy. Washington, DC: School of International Service, American University; 1998. Bräutigam D. Local entrepreneurship in Southeast Asia and Subsaharan Africa: networks and linkages to the global economy. Washington, DC: School of International Service, American University; 1998.
19.
go back to reference Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900–11.CrossRefPubMed Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900–11.CrossRefPubMed
21.
go back to reference WHO. Method for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. p. 12–82. WHO. Method for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. p. 12–82.
22.
go back to reference Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, Li CF. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J. 2013;12:409.CrossRefPubMedCentralPubMed Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, Li CF. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J. 2013;12:409.CrossRefPubMedCentralPubMed
23.
24.
go back to reference WHO. Methods and techniques for clinical trials on antimalarial efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008. WHO. Methods and techniques for clinical trials on antimalarial efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008.
25.
go back to reference Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014;13:309.CrossRefPubMedCentralPubMed Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014;13:309.CrossRefPubMedCentralPubMed
26.
go back to reference Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006;5:127.CrossRefPubMedCentralPubMed Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006;5:127.CrossRefPubMedCentralPubMed
28.
29.
go back to reference Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.CrossRefPubMed Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.CrossRefPubMed
31.
go back to reference Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeug N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57:914–23.CrossRefPubMedCentralPubMed Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeug N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57:914–23.CrossRefPubMedCentralPubMed
32.
go back to reference Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, Yi P, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics. 2011;12:391.CrossRefPubMedCentralPubMed Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, Yi P, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics. 2011;12:391.CrossRefPubMedCentralPubMed
33.
go back to reference Chotivanich K, Tripura R, Das D, Yi P, Day N, Pukrittayakamee S. Laboratory detection of artemisinin resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2014;58:3157–61.CrossRefPubMedCentralPubMed Chotivanich K, Tripura R, Das D, Yi P, Day N, Pukrittayakamee S. Laboratory detection of artemisinin resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2014;58:3157–61.CrossRefPubMedCentralPubMed
34.
go back to reference Sun XD, Zhang ZX, Liu DQ. Clinical study on the efficacy of dihyroartemisinin and piperaquine in treatment of multi-drug resistant Plasmodium falciparum [in Chinese]. Chin Trop Med. 2006;6:211–2. Sun XD, Zhang ZX, Liu DQ. Clinical study on the efficacy of dihyroartemisinin and piperaquine in treatment of multi-drug resistant Plasmodium falciparum [in Chinese]. Chin Trop Med. 2006;6:211–2.
35.
go back to reference Liu H, Yang HL, Zhang J, Li CF, Nie RH, Wang HY. Clinical trial on efficacy of compound dihydroartemisinin-piperaquine for treatment of uncomplicated falciparum malaria in Myanmar [in Chinese]. Chin J Parasit Parasitic Dis. 2011;29:296–8. Liu H, Yang HL, Zhang J, Li CF, Nie RH, Wang HY. Clinical trial on efficacy of compound dihydroartemisinin-piperaquine for treatment of uncomplicated falciparum malaria in Myanmar [in Chinese]. Chin J Parasit Parasitic Dis. 2011;29:296–8.
36.
go back to reference Huang F, Tang LH, Yang HL, Zhou SS, Sun XD, Liu H. Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China-Myanmar border. Malar J. 2012;11:278.CrossRefPubMedCentralPubMed Huang F, Tang LH, Yang HL, Zhou SS, Sun XD, Liu H. Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China-Myanmar border. Malar J. 2012;11:278.CrossRefPubMedCentralPubMed
38.
go back to reference WHO. Methods and techniques for assessing exposures to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011. WHO. Methods and techniques for assessing exposures to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011.
39.
go back to reference WHO. Status report on artemisinin resistance. Geneva: World Health Organization; 2014. WHO. Status report on artemisinin resistance. Geneva: World Health Organization; 2014.
40.
go back to reference Kyaw TT, Hlaing T, Thimasarn K, Mon KM, Galappaththy G, Plasai V, et al. Containing artemisinin resistance of Plasmodium falciparum in Myanmar: Achievements, challenges and the way forward. Southeast Asia J Public Health. 2014;3:90–4. Kyaw TT, Hlaing T, Thimasarn K, Mon KM, Galappaththy G, Plasai V, et al. Containing artemisinin resistance of Plasmodium falciparum in Myanmar: Achievements, challenges and the way forward. Southeast Asia J Public Health. 2014;3:90–4.
41.
go back to reference Yuan LL, Zhao H, Lanou Wu L, Li XM, Parkerd D, Xu SH, et al. Plasmodium falciparum populations from northeastern Myanmar display high levels of genetic diversity at multiple antigenic loci. Acta Trop. 2013;125:53–9.CrossRefPubMedCentralPubMed Yuan LL, Zhao H, Lanou Wu L, Li XM, Parkerd D, Xu SH, et al. Plasmodium falciparum populations from northeastern Myanmar display high levels of genetic diversity at multiple antigenic loci. Acta Trop. 2013;125:53–9.CrossRefPubMedCentralPubMed
42.
go back to reference Briena CO, Henricha P, Passia N, Fidock D. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis. 2011;24:570–7.CrossRef Briena CO, Henricha P, Passia N, Fidock D. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis. 2011;24:570–7.CrossRef
43.
go back to reference Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013;29:313–7.CrossRefPubMed Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013;29:313–7.CrossRefPubMed
44.
go back to reference Guerin PJ, Bates SJ, Sibley CH. Global resistance surveillance: ensuring antimalarial efficacy in the future. Curr Opin Infect Dis. 2009;22:593–600.CrossRefPubMed Guerin PJ, Bates SJ, Sibley CH. Global resistance surveillance: ensuring antimalarial efficacy in the future. Curr Opin Infect Dis. 2009;22:593–600.CrossRefPubMed
45.
go back to reference Song JP, Chen PQ, Xu Y. Randomized-control trial of compound dihydroartemisinin in treating uncomplicated falciparum malaria in Hainan Province of China [in Chinese]. J Guangzhou Uni of Trad Chin Med. 2004;21:9–12. Song JP, Chen PQ, Xu Y. Randomized-control trial of compound dihydroartemisinin in treating uncomplicated falciparum malaria in Hainan Province of China [in Chinese]. J Guangzhou Uni of Trad Chin Med. 2004;21:9–12.
46.
go back to reference Wang SQ, Christophel EM, Lin SG. Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan [in Chinese]. Chin J Parasit Parasitic Dis. 2008;26:50–2. Wang SQ, Christophel EM, Lin SG. Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan [in Chinese]. Chin J Parasit Parasitic Dis. 2008;26:50–2.
47.
go back to reference Xia ZG, Yang MN, Zhou SS. Malaria situation in the People’s Republic of China in 2011 [in Chinese]. Chin J Parasitol Parasit Dis. 2012;30:419–22. Xia ZG, Yang MN, Zhou SS. Malaria situation in the People’s Republic of China in 2011 [in Chinese]. Chin J Parasitol Parasit Dis. 2012;30:419–22.
48.
go back to reference Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai–Myanmar border, 1999–2011: an observational study. PLoS Med. 2013;10:e1001398.CrossRefPubMedCentralPubMed Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai–Myanmar border, 1999–2011: an observational study. PLoS Med. 2013;10:e1001398.CrossRefPubMedCentralPubMed
49.
go back to reference White N. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175–81.CrossRefPubMed White N. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175–81.CrossRefPubMed
Metadata
Title
In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013
Authors
Hui Liu
Heng-lin Yang
Lin-hua Tang
Xing-liang Li
Fang Huang
Jia-zhi Wang
Chun-fu Li
Heng-ye Wang
Ren-hua Nie
Xiang-rui Guo
Ying-xue Lin
Mei Li
Jian Wang
Jian-wei Xu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-015-0584-8

Other articles of this Issue 1/2015

Malaria Journal 1/2015 Go to the issue